Adaptive Biotechnologies Corp is primarily active in the biotechnology industry.

Adaptive Biotechnologies Corp faces competition from various companies in the market. Some notable competitors include Pacific Biosciences of California Inc., Illumina Inc., Guardant Health Inc., and QIAGEN N.V. These companies also operate in the field of biotechnology, focusing on next-generation sequencing technologies and providing molecular diagnostic solutions. However, Adaptive Biotechnologies Corp distinguishes itself through its innovative and proprietary immune medicine platform, enabling the study of immune systems. By leveraging its unique technology, Adaptive Biotechnologies Corp maintains a competitive edge in the market.

Adaptive Biotechnologies Corp is a healthcare company specializing in decoding the adaptive immune system to improve patient care. Founded in 2009 by Chad Robins and Harlan Robins, the company's innovative approach focuses on combining high-throughput sequencing with advanced bioinformatics to study the immune system and enable discoveries in various disease areas. Adaptive Bio has collaborations with leading pharmaceutical companies and research institutions worldwide. With its deep understanding of the adaptive immune system, the company aims to develop revolutionary diagnostics and therapies for diseases like cancer, autoimmune disorders, and infectious diseases. Adaptive Biotechnologies Corp is committed to transforming medicine through its cutting-edge technologies and unique insights into the immune system.

Some significant milestones achieved by Adaptive Biotechnologies Corp include the successful completion of their initial public offering (IPO) in June 2019, raising approximately $345 million. They have also entered into collaborations and partnerships with notable organizations, such as Genentech, Microsoft, and Amgen, among others. Adaptive Biotechnologies Corp has made significant advancements in deciphering the adaptive immune system with their proprietary immune medicine platform. This has led to the development of groundbreaking diagnostic tools and therapeutics for various diseases, including cancer. They continue to expand their reach globally and are committed to advancing precision medicine through their innovative approach to harnessing the power of the immune system.

Adaptive Biotechnologies Corp is primarily present in the United States.

Adaptive Biotechnologies Corp represents a strong commitment to revolutionizing the diagnosis and treatment of diseases through its innovative biotechnology solutions. The company's corporate philosophy revolves around harnessing the power of the adaptive immune system to develop precise and accurate diagnostic tests and personalized therapeutics for various diseases. Adaptive Biotechnologies Corp strives to improve patient outcomes by combining cutting-edge technology, computational biology, and extensive research expertise. With an unwavering focus on advancing precision medicine, Adaptive Biotechnologies Corp aims to empower healthcare professionals with the tools they need to make informed decisions and improve the lives of patients.

Analysts currently set an average price target of 20,40 USD for the Adaptive Biotechnologies stock (median: 20,40 USD), implying −18,2 % versus the latest price. The consensus is based on 14 analyst ratings.

Adaptive Biotechnologies Analyytikkojen kursstavoitteet 2026

14 analysts currently rate the Adaptive Biotechnologies stock: 12 recommend buying, 2 holding and 0 selling. For 2026, analysts expect Adaptive Biotechnologies to generate revenue of 286,58 M USD and earnings per share of −0,46 USD.

Adaptive Biotechnologies Analyytikkojen kursstavoitteet 2026

Converted at the current exchange rate, the Adaptive Biotechnologies share trades at 20,43 EUR (23,60 USD).

The Adaptive Biotechnologies share (ADPT) is listed on 5 stock exchanges, including: NASDAQ (ADPT), XETRA (1HM.DE), Frankfurt (1HM.F), München (1HM.MU), Düsseldorf (1HM.DU).

Adaptive Biotechnologies Corp is a biomedical company that focuses on the development of diagnostic tests and therapies to combat cancer and infectious diseases. The company was founded in 2009 and is headquartered in Seattle, Washington.

odotettu liikevaihto Adaptive Biotechnologies on 286,58 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto Adaptive Biotechnologies on −70,07 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

Adaptive Biotechnologies:n hinta-voitto-suhde (P/E) on tällä hetkellä −51,58. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Adaptive Biotechnologies-osakkeen arvostusta.

Adaptive Biotechnologies:n hinta-myynti-suhde (P/S) on tällä hetkellä 12,61. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Adaptive Biotechnologies-osakkeen arvostuskennuslukuna.

Adaptive Biotechnologies:n Eulpool-laatuscore on 3/10.

Adaptive Biotechnologies:n ISIN on US00650F1093. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

Adaptive Biotechnologies:n WKN on A2PLR5. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

Adaptive Biotechnologies:n ticker on ADPT. Tämä pörssinoteeraus käytetään Adaptive Biotechnologies-osakkeiden kauppaan pörssissä.

Adaptive Biotechnologies maksoi osinkoa joka vuosi viimeisten 0 vuoden aikana.

Adaptive Biotechnologies kuuluu sektoriin 'Terveydenhuolto'.

Adaptive Biotechnologies:n osingot jaetaan valuutassa USD.